Software - Application
Compare Stocks
5 / 10Stock Comparison
AIXI vs AIRS vs BBAI vs SKIN vs AMZN
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Information Technology Services
Household & Personal Products
Specialty Retail
AIXI vs AIRS vs BBAI vs SKIN vs AMZN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Software - Application | Medical - Care Facilities | Information Technology Services | Household & Personal Products | Specialty Retail |
| Market Cap | $8M | $216M | $19.73B | $118M | $2.92T |
| Revenue (TTM) | $115M | $158M | $127M | $296M | $742.78B |
| Net Income (TTM) | $-53M | $-18M | $-289M | $-6M | $90.80B |
| Gross Margin | 64.3% | 64.0% | 25.8% | 64.9% | 50.6% |
| Operating Margin | -44.2% | -9.3% | -68.3% | -3.6% | 11.5% |
| Forward P/E | — | — | — | — | 34.8x |
| Total Debt | $46M | $105M | $24M | $379M | $152.99B |
| Cash & Equiv. | $847K | $8M | $87M | $233M | $86.81B |
AIXI vs AIRS vs BBAI vs SKIN vs AMZN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 23 | May 26 | Return |
|---|---|---|---|
| Xiao-I Corporation (AIXI) | 100 | 1.2 | -98.8% |
| AirSculpt Technolog… (AIRS) | 100 | 68.7 | -31.3% |
| BigBear.ai Holdings… (BBAI) | 100 | 170.9 | +70.9% |
| The Beauty Health C… (SKIN) | 100 | 7.2 | -92.8% |
| Amazon.com, Inc. (AMZN) | 100 | 262.5 | +162.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AIXI vs AIRS vs BBAI vs SKIN vs AMZN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AIXI is the #2 pick in this set and the best alternative if growth exposure and defensive is your priority.
- Rev growth 18.8%, EPS growth 52.7%, 3Y rev CAGR 29.3%
- Beta 0.94, current ratio 0.88x
- 18.8% revenue growth vs BBAI's -19.3%
- Beta 0.94 vs AIRS's 3.37
AIRS ranks third and is worth considering specifically for dividends.
- 0.1% yield; the other 4 pay no meaningful dividend
BBAI is the clearest fit if your priority is income & stability.
- Dividend streak 2 yrs, beta 3.31
SKIN is the clearest fit if your priority is value.
- Better valuation composite
AMZN carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 7.0% 10Y total return vs BBAI's -57.6%
- Lower volatility, beta 1.51, Low D/E 37.2%, current ratio 1.05x
- 12.2% margin vs BBAI's -226.7%
- +43.7% vs AIXI's -79.2%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 18.8% revenue growth vs BBAI's -19.3% | |
| Value | Better valuation composite | |
| Quality / Margins | 12.2% margin vs BBAI's -226.7% | |
| Stability / Safety | Beta 0.94 vs AIRS's 3.37 | |
| Dividends | 0.1% yield; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +43.7% vs AIXI's -79.2% | |
| Efficiency (ROA) | 11.5% ROA vs AIXI's -65.3%, ROIC 14.7% vs -34.4% |
AIXI vs AIRS vs BBAI vs SKIN vs AMZN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
AIXI vs AIRS vs BBAI vs SKIN vs AMZN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
AMZN leads in 3 of 6 categories
SKIN leads 1 • BBAI leads 1 • AIXI leads 0 • AIRS leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
AMZN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AMZN is the larger business by revenue, generating $742.8B annually — 6486.8x AIXI's $115M. AMZN is the more profitable business, keeping 12.2% of every revenue dollar as net income compared to BBAI's -2.3%. On growth, AMZN holds the edge at +16.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $115M | $158M | $127M | $296M | $742.8B |
| EBITDAEarnings before interest/tax | -$49M | -$2M | -$75M | $9M | $155.9B |
| Net IncomeAfter-tax profit | -$53M | -$18M | -$289M | -$6M | $90.8B |
| Free Cash FlowCash after capex | -$2M | $2M | -$56M | $29M | -$2.5B |
| Gross MarginGross profit ÷ Revenue | +64.3% | +64.0% | +25.8% | +64.9% | +50.6% |
| Operating MarginEBIT ÷ Revenue | -44.2% | -9.3% | -68.3% | -3.6% | +11.5% |
| Net MarginNet income ÷ Revenue | -45.9% | -11.4% | -2.3% | -2.0% | +12.2% |
| FCF MarginFCF ÷ Revenue | -2.0% | +1.6% | -44.3% | +9.8% | -0.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | -64.9% | -17.8% | -0.9% | -6.7% | +16.6% |
| EPS Growth (YoY)Latest quarter vs prior year | -29.9% | -50.0% | +52.0% | +38.0% | +74.8% |
Valuation Metrics
SKIN leads this category, winning 2 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, AMZN's 20.5x EV/EBITDA is more attractive than SKIN's 7331.2x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $8M | $216M | $19.7B | $118M | $2.92T |
| Enterprise ValueMkt cap + debt − cash | $53M | $313M | $19.7B | $264M | $2.98T |
| Trailing P/EPrice ÷ TTM EPS | -0.45x | -24.71x | -5.09x | -5.69x | 37.82x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | 34.77x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 1.35x |
| EV / EBITDAEnterprise value multiple | — | 31.06x | — | 7331.15x | 20.47x |
| Price / SalesMarket cap ÷ Revenue | 0.11x | 1.20x | 154.51x | 0.39x | 4.07x |
| Price / BookPrice ÷ Book value/share | — | 2.52x | 24.45x | 2.02x | 7.14x |
| Price / FCFMarket cap ÷ FCF | — | — | — | 3.17x | 378.98x |
Profitability & Efficiency
AMZN leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
AMZN delivers a 23.3% return on equity — every $100 of shareholder capital generates $23 in annual profit, vs $-51 for BBAI. BBAI carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to SKIN's 6.20x. On the Piotroski fundamental quality scale (0–9), SKIN scores 7/9 vs AIRS's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -21.8% | -50.7% | -9.4% | +23.3% |
| ROA (TTM)Return on assets | -65.3% | -9.0% | -35.3% | -1.2% | +11.5% |
| ROICReturn on invested capital | -34.4% | -0.8% | -19.5% | -6.8% | +14.7% |
| ROCEReturn on capital employed | -3.4% | -1.0% | -19.6% | -4.5% | +15.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 | 4 | 7 | 6 |
| Debt / EquityFinancial leverage | — | 1.32x | 0.04x | 6.20x | 0.37x |
| Net DebtTotal debt minus cash | $45M | $97M | -$63M | $146M | $66.2B |
| Cash & Equiv.Liquid assets | $846,593 | $8M | $87M | $233M | $86.8B |
| Total DebtShort + long-term debt | $46M | $105M | $24M | $379M | $153.0B |
| Interest CoverageEBIT ÷ Interest expense | -14.13x | -1.82x | -18.17x | 0.81x | 39.96x |
Total Returns (Dividends Reinvested)
AMZN leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AMZN five years ago would be worth $16,476 today (with dividends reinvested), compared to $138 for AIXI. Over the past 12 months, AMZN leads with a +43.7% total return vs AIXI's -79.2%. The 3-year compound annual growth rate (CAGR) favors AMZN at 36.8% vs AIXI's -75.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +68.1% | +87.0% | -28.6% | -35.0% | +19.7% |
| 1-Year ReturnPast 12 months | -79.2% | +35.2% | +36.7% | -35.9% | +43.7% |
| 3-Year ReturnCumulative with dividends | -98.6% | -34.0% | +49.5% | -91.7% | +156.2% |
| 5-Year ReturnCumulative with dividends | -98.6% | -75.6% | -56.9% | -92.9% | +64.8% |
| 10-Year ReturnCumulative with dividends | -98.6% | -75.6% | -57.6% | -91.6% | +697.8% |
| CAGR (3Y)Annualised 3-year return | -75.9% | -12.9% | +14.3% | -56.4% | +36.8% |
Risk & Volatility
Evenly matched — AIXI and AMZN each lead in 1 of 2 comparable metrics.
Risk & Volatility
AIXI is the less volatile stock with a 0.94 beta — it tends to amplify market swings less than AIRS's 3.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMZN currently trades 97.3% from its 52-week high vs AIXI's 18.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.94x | 3.37x | 3.31x | 2.00x | 1.51x |
| 52-Week HighHighest price in past year | $4.02 | $12.00 | $9.39 | $2.69 | $278.56 |
| 52-Week LowLowest price in past year | $0.08 | $1.51 | $2.96 | $0.76 | $185.01 |
| % of 52W HighCurrent price vs 52-week peak | +18.0% | +28.8% | +44.4% | +33.8% | +97.3% |
| RSI (14)Momentum oscillator 0–100 | 49.3 | 70.0 | 63.3 | 52.1 | 81.1 |
| Avg Volume (50D)Average daily shares traded | 60.6M | 3.1M | 34.6M | 760K | 45.5M |
Analyst Outlook
BBAI leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: AIRS as "Hold", BBAI as "Hold", SKIN as "Hold", AMZN as "Buy". Consensus price targets imply 73.4% upside for AIRS (target: $6) vs 13.1% for AMZN (target: $307). AIRS is the only dividend payer here at 0.13% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Hold | Hold | Buy |
| Price TargetConsensus 12-month target | — | $6.00 | $6.00 | $1.30 | $306.77 |
| # AnalystsCovering analysts | — | 5 | 4 | 13 | 94 |
| Dividend YieldAnnual dividend ÷ price | — | +0.1% | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | 2 | — | — |
| Dividend / ShareAnnual DPS | — | $0.00 | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.4% | 0.0% | 0.0% | 0.0% |
AMZN leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SKIN leads in 1 (Valuation Metrics). 1 tied.
AIXI vs AIRS vs BBAI vs SKIN vs AMZN: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is AIXI or AIRS or BBAI or SKIN or AMZN a better buy right now?
For growth investors, Xiao-I Corporation (AIXI) is the stronger pick with 18.
8% revenue growth year-over-year, versus -19. 3% for BigBear. ai Holdings, Inc. (BBAI). Amazon. com, Inc. (AMZN) offers the better valuation at 37. 8x trailing P/E (34. 8x forward), making it the more compelling value choice. Analysts rate Amazon. com, Inc. (AMZN) a "Buy" — based on 94 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AIXI or AIRS or BBAI or SKIN or AMZN?
Over the past 5 years, Amazon.
com, Inc. (AMZN) delivered a total return of +64. 8%, compared to -98. 6% for Xiao-I Corporation (AIXI). Over 10 years, the gap is even starker: AMZN returned +697. 8% versus AIXI's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AIXI or AIRS or BBAI or SKIN or AMZN?
By beta (market sensitivity over 5 years), Xiao-I Corporation (AIXI) is the lower-risk stock at 0.
94β versus AirSculpt Technologies, Inc. 's 3. 37β — meaning AIRS is approximately 257% more volatile than AIXI relative to the S&P 500. On balance sheet safety, BigBear. ai Holdings, Inc. (BBAI) carries a lower debt/equity ratio of 4% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.
04Which is growing faster — AIXI or AIRS or BBAI or SKIN or AMZN?
By revenue growth (latest reported year), Xiao-I Corporation (AIXI) is pulling ahead at 18.
8% versus -19. 3% for BigBear. ai Holdings, Inc. (BBAI). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -77. 4% for AirSculpt Technologies, Inc.. Over a 3-year CAGR, AIXI leads at 29. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AIXI or AIRS or BBAI or SKIN or AMZN?
Amazon.
com, Inc. (AMZN) is the more profitable company, earning 10. 8% net margin versus -230. 2% for BigBear. ai Holdings, Inc. — meaning it keeps 10. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMZN leads at 11. 2% versus -65. 3% for BBAI. At the gross margin level — before operating expenses — AIXI leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is AIXI or AIRS or BBAI or SKIN or AMZN more undervalued right now?
Analyst consensus price targets imply the most upside for AIRS: 73.
4% to $6. 00.
07Which pays a better dividend — AIXI or AIRS or BBAI or SKIN or AMZN?
In this comparison, AIRS (0.
1% yield) pays a dividend. AIXI, BBAI, SKIN, AMZN do not pay a meaningful dividend and should not be held primarily for income.
08Is AIXI or AIRS or BBAI or SKIN or AMZN better for a retirement portfolio?
For long-horizon retirement investors, Amazon.
com, Inc. (AMZN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+697. 8% 10Y return). The Beauty Health Company (SKIN) carries a higher beta of 2. 00 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AMZN: +697. 8%, SKIN: -91. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between AIXI and AIRS and BBAI and SKIN and AMZN?
These companies operate in different sectors (AIXI (Technology) and AIRS (Healthcare) and BBAI (Technology) and SKIN (Consumer Defensive) and AMZN (Consumer Cyclical)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: AIXI is a small-cap high-growth stock; AIRS is a small-cap quality compounder stock; BBAI is a mid-cap quality compounder stock; SKIN is a small-cap quality compounder stock; AMZN is a mega-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.